Gain Therapeutics (GANX) vs Milestone Pharmaceuticals (MIST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Gain Therapeutics (GANX) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 62.4% versus a loss of 84.5%. Over five years, GANX leads with a -87.3% price change compared with -93.8% for MIST. Milestone Pharmaceuticals is the larger company by market cap ($46.2 million vs $44.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | MIST |
|---|---|---|
| Share price | $0.9994 | $0.3711 |
| Market cap | $44.50M | $46.20M |
| 1-day change | -4.82% | -7.06% |
| YTD return | -68.96% | -81.63% |
| 1-year return | -62.43% | -84.54% |
| 5-year return | -87.27% | -93.85% |
| EPS (TTM) | $-0.42 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-20.16M | $-63.06M |
| 52-week high | $4.34 | $3.06 |
| 52-week low | $0.94 | $0.362 |
| Distance from 52-week high | -76.97% | -87.87% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +620.43% | +1479.09% |
| Average volume | 550.22K | 1.53M |
| Shares outstanding | 44.53M | 124.50M |
| Employees | 20 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GANX has outperformed MIST by 22.1 percentage points over the past year.
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
GANX vs MIST FAQ
Which is bigger, Gain Therapeutics or Milestone Pharmaceuticals?
Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $46.20M compared with $44.50M for Gain Therapeutics (GANX).
Which stock has performed better over the past year, GANX or MIST?
GANX returned -62.43% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and Milestone Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.